Pomalyst Combo Appears Effective in Multiple Myeloma Patients Refractory to Revlimid, Trial Reports
Multiple myeloma patients who failed to respond to treatment…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Chinese Regulatory Agency Clears CT103A for Clinical Studies in Relapsed or Refractory Multiple Myeloma
IASO Biotherapeutics and Innovent Biologics are preparing…
Aplidin Prolongs Survival and Time to Disease Progression in Heavily Treated Multiple Myeloma Patients, Phase 3 Trial Shows
Aplidin (plitidepsin) in combination with dexamethasone…
Scientists Find ‘On/off Switch’ of Malignant MM Cancer Cells, May Lead to New Therapies, Study Says
Scientists discovered a set of genes that work as…
FDA Approves Darzalex-Revlimid-dexamethasone Combo to Treat Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug…
Empliciti Combo Prolongs Survival in Difficult-to-Treat Multiple Myeloma, New Phase 2 Trial Data Show
Adding Empliciti (elotuzumab) to a regimen including Pomalyst…
